Repligen (RGEN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 May, 2026Opening remarks and agenda
Meeting opened virtually to ensure accessibility for all shareholders worldwide.
Chair introduced the agenda and directed participants to the virtual meeting website for materials and rules of conduct.
Introductions included board members, executive team, independent auditor, and inspector of elections.
Board and executive committee updates
Board members and executive officers were introduced, including the President and CEO, CFO, and General Counsel.
Shareholder proposals
Three proposals were presented: election of nine directors, ratification of Ernst & Young as auditor, and a non-binding advisory vote on executive compensation.
Board recommended voting in favor of all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Repligen
- 2026 outlook features robust growth, margin expansion, and strategic investments for long-term scale.RGEN
Leerink Global Healthcare Conference 202613 May 2026 - Strong Q1, robust growth in key segments, and strategic expansion initiatives drive optimism.RGEN
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 delivered 15% revenue growth, margin expansion, and raised FY26 EPS guidance.RGEN
Q1 202611 May 2026 - Board recommends re-electing directors, citing progress on internal controls and diversity.RGEN
Proxy filing27 Apr 2026 - Double-digit growth in FY25 with strong FY26 outlook and margin expansion despite headwinds.RGEN
Q4 202510 Apr 2026 - Proxy covers director elections, auditor ratification, executive pay, and strong 2025 growth.RGEN
Proxy filing2 Apr 2026 - Key votes include board elections, auditor ratification, and executive pay approval.RGEN
Proxy filing2 Apr 2026 - Broad innovation, strong execution, and digital focus drive multi-year growth outlook.RGEN
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Bioprocessing leader targets $810M–$840M FY26 revenue and ~30% EBITDA margin by 2030.RGEN
Investor presentation10 Mar 2026